Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
More about Open Access at the CrickAuthors list
Annika Fendler Lewis Au Scott Shepherd Fiona Byrne Maddalena Cerrone Laura Amanda Boos Karolina Rzeniewicz William Gordon Benjamin Shum Camille L Gerard Barry Ward Wenyi Xie Andreas M Schmitt Nalinie Joharatnam-Hogan Georgina H Cornish Martin Pule Leila Mekkaoui Kevin Ng Eleanor Carlyle Kim Edmonds Lyra Del Rosario Sarah Sarker Karla Lingard Mary Mangwende Lucy Holt Hamid Ahmod Richard Stone Camila Gomes Helen R Flynn Ana Agua-Doce Philip Hobson Simon Caidan Michael Howell Mary Wu Robert Goldstone Marg Crawford Laura Cubitt Harshil Patel Mike Gavrielides Emma Nye Bram Snijders James Macrae Jerome Nicod Firza Gronthoud Robyn L Shea Christina Messiou David Cunningham Ian Chau Naureen Starling Nicholas Turner Liam Welsh Nicholas van As Robin L Jones Joanne Droney Susana Banerjee Kate C Tatham Shaman Jhanji Mary O’Brien Olivia Curtis Kevin Harrington Shreerang Bhide Jessica Bazin Anna Robinson Clemency Stephenson Tim Slattery Yasir Khan Zayd Tippu Isla Leslie Spyridon Gennatas Alicia Okines Alison Reid Kate Young Andrew JS Furness Lisa Pickering Sonia Gandhi Steve Gamblin Charles Swanton The Crick COVID-19 Consortium Emma Nicholson Sacheen Kumar Nadia Yousaf Katalin Wilkinson Anthony Swerdlow Ruth Harvey George Kassiotis James Larkin Robert Wilkinson Samra Turajlic The CAPTURE consortium Toggle all authors (89)
Abstract
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
Journal details
Journal Nature Cancer
Volume 2
Issue number 12
Pages 1321-1337
Available online
Publication date
Full text links
Publisher website (DOI) 10.1038/s43018-021-00275-9
Europe PubMed Central 35121900
Pubmed 35121900
Keywords
Related topics
- Tumour Biology
- Structural Biology & Biophysics
- Stem Cells
- Signalling & Oncogenes
- Neurosciences
- Model Organisms
- Metabolism
- Infectious Disease
- Immunology
- Human Biology & Physiology
- Genome Integrity & Repair
- Genetics & Genomics
- Developmental Biology
- Computational & Systems Biology
- Chemical Biology & High Throughput
- Cell Cycle & Chromosomes
- Cell Biology
- Biochemistry & Proteomics
Type of publication